<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806506</url>
  </required_header>
  <id_info>
    <org_study_id>KBN N N403 3882 33</org_study_id>
    <nct_id>NCT01806506</nct_id>
  </id_info>
  <brief_title>Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity</brief_title>
  <official_title>Randomized Clinical Trial Comparing Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity and Underlying Metabolic and Hormonal Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bariatric surgery is the most effective treatment for morbid obesity. Roux-en-Y gastric
      bypass (RYGB) is a bariatric procedure with known safety and effectiveness. Laparoscopic
      sleeve gastrectomy (LSG) is a newer procedure gaining popularity. The aim of the study is to
      compare outcomes of these two surgical methods in terms of weight loss, improvement of common
      comorbidities of obesity and influence on metabolic and hormonal status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Authors of the study believe that a more detailed head-to-head comparison of RYGB and LSG is
      necessary. The former method is the established &quot;gold standard&quot; procedure with good outcomes
      reported in many studies. However it is much more complex and the learning curve is longer.
      The latter method was introduced as an initial procedure in superobese patients because of
      its relative simplicity. It produced good outcomes in this population of superobese patients
      and surgeons in some centers started to use it as a primary bariatric procedure. RYGB is a
      restrictive and partially malabsorptive procedure and it is believed to have additional
      benefits in patients with metabolic disorders such as type 2 diabetes and dyslipidemia.
      Purely restrictive procedures such as LSG are theoretically less beneficial in this group of
      patients. In the present study authors will look at weight loss as well as improvement in
      comorbidities and several biochemical parameters and indices to assess also metabolic action
      of these two procedures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excess Weight Loss From Baseline</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Weight loss measured as a percentage of excess weight lost is one of the most commonly used and accepted outcome measure in clinical trials evaluating bariatric surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Complications</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Complications are defined as any negative deviation from the normal postoperative course. Complications of bariatric surgery include but are not limited to: gastrointestinal leak, intrabdominal bleeding, gastrointestinal bleeding, gastrointestinal stricture, gastrointestinal fistula, marginal ulceration, internal hernia, bowel obstruction, deep vein thrombosis, pulmonary embolism, wound infection, seroma, fascial dehiscence, abdominal hernia, gallstone formation, dehydration, nutritional deficiencies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comorbidities Prevalence Changes</measure>
    <time_frame>Evaluation at baseline and 1, 6 and 12 months after surgery</time_frame>
    <description>Number of patients with comorbidities such as: type 2 diabetes mellitus, arterial hypertension, dyslipidemia, obstructive sleep apnea, degenerative arthritis, gallbladder disease, gastro-esophageal reflux disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight From Baseline</measure>
    <time_frame>Evaluation at baseline and 12 months after surgery</time_frame>
    <description>Absolute weight loss (in kilograms) is evaluated. It is one of the most commonly used and accepted outcome measures in clinical trials evaluating bariatric surgery. It is more dependent on the initial weight of a study participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI From Baseline</measure>
    <time_frame>Baseline and 12 months after surgery</time_frame>
    <description>Assessment of Body Mass Index (weight divided by height in meters squared) change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Total Cholesterol at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma total cholesterol concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HDL at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma high density lipoprotein (HDL) cholesterol concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma LDL at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma low density lipoprotein (LDL) cholesterol concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Triglycerides at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma triglycerides concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucose at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma glucose concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Insulin at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma insulin concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma C-peptide at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Fasting plasma C-peptide concentration in patients 12 months after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA Index at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Insulin resistance (IR) measured with the homeostatic model assessment (HOMA) method. In the published studies the HOMA model correlated with estimates using the reference euglycemic clamp method. The following equation is used: HOMA-IR = (fasting plasma glucose concentration [mmol/L] x fasting plasma insulin concentration [miliunits/L])/22.5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>The proportion of glycosylated hemoglobin (HbA1c) [%] is measured to assesses the average plasma glucose concentration and regulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma CRP at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>C-reactive protein (CRP) is used as a marker of inflammation. It may be also used in the assessment of heart disease risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Uric Acid at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Hyperuricemia is associated with metabolic syndrome and obesity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Ghrelin at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Ghrelin is an appetite-stimulating hormone produced in the fundus of the stomach. Its concentration may change after some bariatric procedures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Leptin at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Leptin is one of the adipose-derived hormones that causes inhibition of appetite. Elevated leptin levels are associated with obesity, inflammation, metabolic syndrome and cardiovascular disease. Weight loss leads to a decline in leptin concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Glucagon at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Glucagon is synthesized and secreted from alpha cells of the pancreas. It leads to elevation of the plasma glucose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma IGF-1 at 12 Months</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Insulin like growth factor 1 (IGF-1) is similar in structure to insulin. It has anabolic effects. Its levels may be related to BMI and level of nutrition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AST Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALT Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>INR</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GGT Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH Level</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life Questionnaire Score</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Quality of life questionnaire score at 12 months(WHO-Bref Quality of Life questionnaire)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pulmonary Function Changes at 12 Months</measure>
    <time_frame>Baseline and 12 months from surgery</time_frame>
    <description>Spirometry and plethysmography results are used to assess pulmonary function before and after surgery.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Morbid Obesity</condition>
  <condition>Metabolic Syndrome X</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Dyslipidemia</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Laparoscopic sleeve gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Roux-en-Y Gastric Bypass</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic sleeve gastrectomy</intervention_name>
    <description>Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.</description>
    <arm_group_label>Laparoscopic sleeve gastrectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Roux-en-Y Gastric Bypass</intervention_name>
    <description>Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.</description>
    <arm_group_label>Roux-en-Y Gastric Bypass</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI≥40 kg/m2

          -  BMI≥35 kg/m2 with at least one comorbidity associated with obesity

        Exclusion Criteria:

          -  BMI &gt; 60 kg/m2

          -  poorly controlled significant medical or psychiatric disorders

          -  active alcohol or substance abuse

          -  active duodenal/gastric ulcer disease

          -  difficult to treat gastro-esophageal reflux disease with a large hiatal hernia

          -  previous major gastrointestinal surgery

          -  diagnosed or suspected malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rafał Paluszkiewicz, Prof. MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Warsaw</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of General, Transplant and Liver Surgery, Public Central Teaching Hospital, Medical University of Warsaaw</name>
      <address>
        <city>Warsaw</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.wum.edu.pl</url>
    <description>Medical University of Warsaw web site</description>
  </link>
  <link>
    <url>https://hepaclin.wum.edu.pl/en</url>
    <description>Chair and Department of General Transplant and Liver Surgery, Medical University of Warsaw</description>
  </link>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>January 31, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <results_first_submitted>October 8, 2018</results_first_submitted>
  <results_first_submitted_qc>October 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 20, 2019</results_first_posted>
  <last_update_submitted>October 8, 2018</last_update_submitted>
  <last_update_submitted_qc>October 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bariatric surgery</keyword>
  <keyword>Gastric bypass</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Lipoproteins</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Incretins</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The patients were recruited from the population of patients referred for bariatric consultation to the outpatient clinic of the Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Poland. The recruitment started in November 2008 and finished when the planned number of patients had been recruited for the study.</recruitment_details>
      <pre_assignment_details>Eighty six patients meeting the general criteria for bariatric surgery were evaluated for eligibility for the study. Six patients did not meet eligibility criteria (age &gt; 60 years in 5 patients, suspicion of malignancy in 1 patient) and 8 patients decided not to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Laparoscopic Sleeve Gastrectomy</title>
          <description>The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
Laparoscopic sleeve gastrectomy: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.</description>
        </group>
        <group group_id="P2">
          <title>Roux-en-Y Gastric Bypass</title>
          <description>The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
Roux-en-Y Gastric Bypass: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1 Month</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>3 Months</title>
              <participants_list>
                <participants group_id="P1" count="35">1 patient (reason - lost contact)</participants>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>6 Months</title>
              <participants_list>
                <participants group_id="P1" count="34">1 patient (reason - lost contact)</participants>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>9 Months</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35">1 patient (reason - lost contact)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laparoscopic Sleeve Gastrectomy</title>
          <description>The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
Laparoscopic sleeve gastrectomy: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.</description>
        </group>
        <group group_id="B2">
          <title>Roux-en-Y Gastric Bypass</title>
          <description>The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
Roux-en-Y Gastric Bypass: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="10.6"/>
                    <measurement group_id="B2" value="43.9" spread="10.8"/>
                    <measurement group_id="B3" value="44.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Excess Weight Loss From Baseline</title>
        <description>Weight loss measured as a percentage of excess weight lost is one of the most commonly used and accepted outcome measure in clinical trials evaluating bariatric surgery.</description>
        <time_frame>12 months after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laparoscopic Sleeve Gastrectomy</title>
            <description>The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
Laparoscopic sleeve gastrectomy: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.</description>
          </group>
          <group group_id="O2">
            <title>Roux-en-Y Gastric Bypass</title>
            <description>The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
Roux-en-Y Gastric Bypass: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.</description>
          </group>
        </group_list>
        <measure>
          <title>Excess Weight Loss From Baseline</title>
          <description>Weight loss measured as a percentage of excess weight lost is one of the most commonly used and accepted outcome measure in clinical trials evaluating bariatric surgery.</description>
          <units>percentage of EWL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.8" spread="19.3"/>
                    <measurement group_id="O2" value="64.2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Complications</title>
        <description>Complications are defined as any negative deviation from the normal postoperative course. Complications of bariatric surgery include but are not limited to: gastrointestinal leak, intrabdominal bleeding, gastrointestinal bleeding, gastrointestinal stricture, gastrointestinal fistula, marginal ulceration, internal hernia, bowel obstruction, deep vein thrombosis, pulmonary embolism, wound infection, seroma, fascial dehiscence, abdominal hernia, gallstone formation, dehydration, nutritional deficiencies</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comorbidities Prevalence Changes</title>
        <description>Number of patients with comorbidities such as: type 2 diabetes mellitus, arterial hypertension, dyslipidemia, obstructive sleep apnea, degenerative arthritis, gallbladder disease, gastro-esophageal reflux disease.</description>
        <time_frame>Evaluation at baseline and 1, 6 and 12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight From Baseline</title>
        <description>Absolute weight loss (in kilograms) is evaluated. It is one of the most commonly used and accepted outcome measures in clinical trials evaluating bariatric surgery. It is more dependent on the initial weight of a study participant.</description>
        <time_frame>Evaluation at baseline and 12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI From Baseline</title>
        <description>Assessment of Body Mass Index (weight divided by height in meters squared) change from baseline.</description>
        <time_frame>Baseline and 12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Total Cholesterol at 12 Months</title>
        <description>Fasting plasma total cholesterol concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma HDL at 12 Months</title>
        <description>Fasting plasma high density lipoprotein (HDL) cholesterol concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma LDL at 12 Months</title>
        <description>Fasting plasma low density lipoprotein (LDL) cholesterol concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Triglycerides at 12 Months</title>
        <description>Fasting plasma triglycerides concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucose at 12 Months</title>
        <description>Fasting plasma glucose concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Insulin at 12 Months</title>
        <description>Fasting plasma insulin concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma C-peptide at 12 Months</title>
        <description>Fasting plasma C-peptide concentration in patients 12 months after surgery.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOMA Index at 12 Months</title>
        <description>Insulin resistance (IR) measured with the homeostatic model assessment (HOMA) method. In the published studies the HOMA model correlated with estimates using the reference euglycemic clamp method. The following equation is used: HOMA-IR = (fasting plasma glucose concentration [mmol/L] x fasting plasma insulin concentration [miliunits/L])/22.5</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c at 12 Months</title>
        <description>The proportion of glycosylated hemoglobin (HbA1c) [%] is measured to assesses the average plasma glucose concentration and regulation.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma CRP at 12 Months</title>
        <description>C-reactive protein (CRP) is used as a marker of inflammation. It may be also used in the assessment of heart disease risk.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Uric Acid at 12 Months</title>
        <description>Hyperuricemia is associated with metabolic syndrome and obesity.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Ghrelin at 12 Months</title>
        <description>Ghrelin is an appetite-stimulating hormone produced in the fundus of the stomach. Its concentration may change after some bariatric procedures.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Leptin at 12 Months</title>
        <description>Leptin is one of the adipose-derived hormones that causes inhibition of appetite. Elevated leptin levels are associated with obesity, inflammation, metabolic syndrome and cardiovascular disease. Weight loss leads to a decline in leptin concentrations.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Glucagon at 12 Months</title>
        <description>Glucagon is synthesized and secreted from alpha cells of the pancreas. It leads to elevation of the plasma glucose.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma IGF-1 at 12 Months</title>
        <description>Insulin like growth factor 1 (IGF-1) is similar in structure to insulin. It has anabolic effects. Its levels may be related to BMI and level of nutrition.</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AST Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALT Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>INR</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albumin Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GGT Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ALP Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDH Level</title>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quality of Life Questionnaire Score</title>
        <description>Quality of life questionnaire score at 12 months(WHO-Bref Quality of Life questionnaire)</description>
        <time_frame>12 months after surgery</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pulmonary Function Changes at 12 Months</title>
        <description>Spirometry and plethysmography results are used to assess pulmonary function before and after surgery.</description>
        <time_frame>Baseline and 12 months from surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Laparoscopic Sleeve Gastrectomy</title>
          <description>The group of morbidly obese patients assigned to laparoscopic sleeve gastrectomy.
Laparoscopic sleeve gastrectomy: Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.</description>
        </group>
        <group group_id="E2">
          <title>Roux-en-Y Gastric Bypass</title>
          <description>The group of morbidly obese patients assigned to Roux-en-Y gastric bypass.
Roux-en-Y Gastric Bypass: Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>gastric leak</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric leak</sub_title>
                <description>Non-symptomatic gastric leak observed in a water-soluble contrast swallow study. Treated with relparoscopy and drainage with no further complications.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="bleeding">Bleeding</sub_title>
                <description>Intragastric bleeding - one case treated laparoscopically, the other required reoperation</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>wound infection</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title vocab="seroma">Fluid collection</sub_title>
                <description>Seroma</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Piotr Kalinowski</name_or_title>
      <organization>Department of General, Transplant and Liver Surgery, Medical University of Warsaw</organization>
      <phone>0048 22 599 2546</phone>
      <email>kalip@o2.pl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

